Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice

BACKGROUND: Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes (T2D). Since no trial has directly compared these two classes of drugs, we perf...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cardiovasc Diabetol
Glavni autori: Longato, Enrico, Di Camillo, Barbara, Sparacino, Giovanni, Tramontan, Lara, Avogaro, Angelo, Fadini, Gian Paolo
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2020
Teme:
Original Investigation
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7288543/
https://ncbi.nlm.nih.gov/pubmed/32522260
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01049-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items